SecBot SecBot
6-K ·Filed Jul 21, 2026

DRTS

Alpha Tau Medical Ltd.
BULLISH
Impact 8/10
Horizondays Processed3mo ago SEC0001213900-26-079822
Notable filing: 6-K
Actionable Insight ▲ Bullish

This is a transformative clinical data readout for a pre-revenue biotech. The 100% ORR and 18.2-month OS substantially exceed historical benchmarks, and the FDA discussion for a larger U.S. study adds a clear near-term catalyst. Expect significant upside momentum; monitor for any equity offering to fund the larger trial.

DirectionBullish
Confidencehigh
Horizondays

Alpha DaRT

▲ Bullish Named in this 6-K
Impact
Phase
Pivotal (PMA submission ongoing for cSCC); Phase 2 pilot for glioblastoma (REGAIN); Pilot for pancreatic cancer (IMPACT)
Time to market
The ReSTART pivotal trial for recurrent cSCC completed enrollment in May 2026 and the first PMA module was submitted in January 2026. If the modular PMA process proceeds smoothly, a US approval decision could come in late 2027 or 2028. Alpha DaRT already has marketing approval in Japan for head and neck cancer and in Israel for SCC of the skin and oral cavity.
Next catalyst
None dated

What to watchThe REGAIN interim data (all 8 patients alive, median survival not reached at 6.9 months follow-up) was released Nov 15, with an investor call on Nov 16. The next major catalyst is the IMPACT pancreatic cancer pilot study data expected in early 2027, and continued progress on the modular PMA submission for cSCC. Q3 2026 earnings are scheduled for Nov 24. Watch for any PMA submission completion announcements for cSCC, which would mark the clearest path to a US approval decision.

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$13.32
T+0 close · Jul 21, 2026 · via day close
Latest settled
+3.15%
T+60 · $13.74
Vs SPY
−0.82%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 21 $13.32entry
  2. T+1 · 4mo ago −2.33%α −2.21% · $13.01
  3. T+5 · 4mo ago −8.33%α −7.11% · $12.21
  4. T+20 · 3mo ago +7.06%α +4.50% · $14.26
  5. T+60 · 5w ago +3.15%α −0.82% · $13.74
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Alpha Tau reported positive clinical data from a study of Alpha DaRT in combination with pembrolizumab in elderly patients with locally advanced or metastatic head and neck squamous cell carcinoma (HNSCC). The combination produced a 100% objective response rate (ORR) and a median overall survival of 18.2 months among evaluable patients, significantly exceeding historical benchmarks for pembrolizumab monotherapy (19% ORR, 12.3 months OS). The trial met its pre-specified success criterion, and the company is discussing a larger U.S. study with the FDA, representing a major pipeline catalyst for this pre-revenue oncology company.

Key Facts

  • Alpha DaRT plus pembrolizumab produced a 100% objective response rate (ORR) in 9 evaluable patients with HNSCC, vs. ~19% historical benchmark for pembrolizumab monotherapy.
  • Median overall survival was 18.2 months, vs. 12.3 months for pembrolizumab monotherapy in KEYNOTE-048.
  • Median progression-free survival was 5.4 months, vs. 3.2 months for pembrolizumab monotherapy.
  • No Alpha DaRT-related serious adverse events were observed; only two Grade 1 adverse events were reported.
  • The trial met its pre-specified success criterion (more than six patients responding), and enrollment was concluded.
  • Company is in ongoing discussions with the FDA regarding a larger U.S. study of the combination.

Financial Impact

No financial figures reported; company is pre-revenue. The positive data is a significant pipeline catalyst that could accelerate regulatory pathway and partnership potential.

Risk Factors

  • Small sample size (9 evaluable patients), results may not replicate in larger, controlled studies.
  • Single-center, open-label, single-arm design limits comparability to standard of care.
  • Company is pre-revenue and will require additional capital to fund larger trials and potential commercialization.

Market Snapshot

Exchange
Nasdaq
Sector
Surgical & Medical Instruments & Apparatus
Analyst Consensus
82% bullish (11 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001213900-26-079822
Document: ea0298609-6k_alpha.htm0001213900-26-079822
Document: 0001213900-26-079822-index-headers.html0001213900-26-079822
Document: 0001213900-26-079822-index.html0001213900-26-079822
Document: 0001213900-26-079822.txt0001213900-26-079822

US Market Status

Market Closed · Opens in 7h 58m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 21, 2026